Kabra Drugs Ltd Financial Ratios
KABRADRUGSLTD · Healthcare · Current price
P/E ratio
6.4x
P/B ratio
1.6x
ROE
18.3%
ROCE
-8.0%
Debt / Equity
0.03
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 6.4x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 1.6x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 18.3% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | -8.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.03 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Kabra Drugs Ltd's latest numbers.
Kabra Drugs Ltd profitability
Kabra Drugs Ltd generates a return on equity of 18.3% and a return on capital employed of -8.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.03 and a P/E of 6.4x, Kabra Drugs Ltd is conservatively financed. Our overall business-quality score for the company is 3.7 / 10.
Understand the ratios
More on Kabra Drugs Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.